SOURCE: Optasia Medical

Optasia Medical

May 01, 2013 07:00 ET

Novel Osteoporosis Diagnostic TBS iNsight Now Available in the United States

SUDBURY, MA--(Marketwired - May 1, 2013) - A novel method for assessing osteoporosis, TBS iNsight®, is now available in the United States. Optasia Medical, a leading image analysis software applications provider today announced that it has reached an agreement with Medimaps Group to distribute TBS iNsight® in the United States. TBS iNsight is a unique software application that assesses bone microarchitecture (expressed as the TBS - Trabecular Bone Score) in routine clinical practice directly from Dual X-Ray Absorptiometry (DXA) images used for bone densitometry.

"We are very excited to partner with Medimaps on making TBS iNsight available to current owners of DXA scanners in the United States," said Peter Steiger, Optasia Medical's Chief Executive Officer. "It is well documented that more osteoporotic fractures occur in patients who are not considered osteoporotic by bone densitometry (BMD) alone, yet BMD remains the only diagnostic method available to most patients. Together with SpineAnalyzer™, TBS iNsight will allow Optasia Medical to offer its customers solutions for more comprehensive osteoporosis evaluation and better risk assessment for future osteoporotic fractures."

Gabriel Tirouflet, Chief Executive Officer of Medimaps Group, added: "The calculation of TBS seamlessly integrates into the workflow of measuring BMD and is fully automated. A significant body of literature has shown how TBS can help improve the prediction of future osteoporotic fracture risk in a clinically meaningful way. We're excited to partner with Optasia in bringing valuable new tools for the management of osteoporosis to the US market."

Both SpineAnalyzer and TBS iNsight have been cleared for marketing by the FDA. For more information on Optasia Medical and SpineAnalyzer, please visit www.spineanalyzer.com. For more information on Medimaps and TBS iNsight, please visit www.tbsinsight.com.

About Optasia Medical
Optasia makes software that facilitates the reading of x-rays for the management of musculoskeletal diseases. Our products are used in clinical trials and by physicians to identify and monitor patients who will benefit from treatment. With Optasia Medical's automated workflow tools, x-rays can be evaluated more rapidly, more accurately and more reproducibly.

About Medimaps Group
Medimaps group -- a Swiss company -- developed the patented and proprietary TBS algorithm to compute bone microarchitectural texture in the context of managing osteoporosis. The company is adapting TBS for dental and orthopedics applications to optimize implant surgery planning based on patients' bone texture.

Contact Information